Chijioke Bennett

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 652 citations · Full text

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Shabir A. Madhi, Dhayendre Moodley, Sherika Hanley et al. · The Lancet HIV · 2022 · 65 citations · Full text

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson et al. · Scientific Reports · 2023 · 46 citations · Full text

Genetics, Immunology, Immunodominance +16

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · 2021 · 42 citations · Full text

Immunology, Preliminary Efficacy, Covid-19 Epidemiology +16

Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson et al. · 2022 · 16 citations · Full text

Vaccination, Vaccine Development, Omicron Sub-lineages +13